Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
The Hill: Big Pharma lost in court — Congress must not bail it out
For the last three years, some of the most profitable corporations in the world spent millions of dollars in court attempting to reverse the biggest defeat the pharmaceutical industry suffered in decades. The Supreme Court recently declined even to hear their cases. For these companies, the legal fight is now over. But the pharmaceutical industry’s […]
Patient Testimonies
ICYMI: Merith Basey Op-Ed in The Hill: “Big Pharma lost in court. Congress shouldn't bail them out.”
Basey argues lawmakers should not hand pharmaceutical companies in Congress what they failed to win in court. WASHINGTON, D.C. — Following the Supreme Court’s decision to reject petitions from six major drugmakers seeking to overturn Medicare drug price negotiation, Patients For Affordable Drugs CEO Merith Basey is urging Congress to protect and strengthen the program rather than weaken […]
News and Reports
Epoch Times Video: The Loophole Drug Makers Use to Keep Prices High
News and Reports
IP Watchdog: SCOTUS’ Hikma Ruling Changes the Game for Induced Infringement Pleadings
Patients For Affordable Drugs CEO Merith Basey said in a statement today that the decision “protects an important pathway for bringing lower-cost generic medicines to patients. Had the Court ruled the other way, generic manufacturers could have faced increased legal risk when following the rules established by Congress and the FDA.”
News and Reports
Fierce Pharma: It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
On Thursday, Patients For Affordable Drugs CEO Merith Basey applauded the decision, saying that it “protects an important pathway for bringing lower-cost generic medicines to patients.” “Had the court ruled the other way, generic manufacturers could have faced increased legal risk when following the rules established by Congress and the FDA. That would have meant […]
Press Releases
WASHINGTON, D.C. — Today, the U.S. Supreme Court unanimously ruled in favor of Hikma in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., preserving a critical pathway that allows lower-cost generic drugs to come to market. The case focused on “skinny labeling,” a long-standing process that allows generic manufacturers to seek approval for off-patent uses of medicines while still […]
News and Reports
The Canadian approval has intensified pressure on US regulators to act. Advocacy groups such as Patients for Affordable Drugs have launched campaigns urging the Food and Drug Administration to expedite generic applications for semaglutide. Legislation has been introduced in Congress to limit patent evergreening, but its prospects remain uncertain.